Eve & Co confirms second German supply deal for sale of dried cannabis
Category: #business  By Mateen Dalal  Date: 2019-05-31
  • share
  • Twitter
  • Facebook
  • LinkedIn

Eve & Co confirms second German supply deal for sale of dried cannabis

It expects to begin shipments following the estimated Q2 2019 completion of its 780,000 square foot greenhouse extension

Eve & Co has recently announced that Natural MedCo Ltd, its wholly owned subsidiary has entered into a second binding non-exclusive supply deal for the sale of dried cannabis to a distributor and importer in Germany.

Sources close to the matter mentioned that the supply agreement is for an early term of three years and is automatically renewable for two succeeding two-year terms unless it is cancelled by the parties at the end of the renewal or initial term. For the first two months, the German supplier has agreed to buy 500 kg of dried cannabis per month, after which it will purchase a maximum of 5,000 kilograms and a minimum of 1,000 kilograms a month for the next 22 months.

Apparently, the company expects to begin shipments following the estimated Q2 2019 completion of its 780,000 square foot greenhouse extension, and the expected approval thereof from Health Canada.

According to President and CEO of Eve & Co., Melinda Rombouts, this is a very substantial supply deal for Eve & Co as it offers additional access into the German market. The timing fits well with the company’s expected extension facilities coming online and the related acceleration of production, Rombouts said.

Seemingly, under the supply agreement, the sale and purchase of dried cannabis are subject to several conditions precedent, including applicable Germany and Canadian export and import authorizations, and receipt of all requisite regulatory approvals.

Eve & Co has also reportedly announced that the German distributor and importer with respect to the initial German supply agreement of Eve & Co, as announced on 30 Jan 2019, has now received the essential import license from the German government. The company is currently in the process of seeking the essential export permit from Health Canada and expects that it will start shipping product pursuant to this supply deal by the third quarter of 2019.

Source Credit: https://www.globenewswire.com/news-release/2019/05/29/1856759/0/en/Eve-Co-Announces-Second-German-Supply-Agreement-Provides-Update-on-First-German-Supply-Agreement.html

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Peraton to acquire innovative IT solutions provider Solers Inc.
Peraton to acquire innovative IT solutions provider Solers Inc.
By Mateen Dalal

Virginia-based Peraton, a defense and intelligence contractor owned by private equity firm Veritas Capital, reportedly announced that it has signed a definitive agreement to acquire Solers Inc., a leading provider of software development and cybersec...

Forty Seven publishes data on Phase 1b/2 clinical trial of 5F9
Forty Seven publishes data on Phase 1b/2 clinical trial of 5F9
By Mateen Dalal

A clinical-stage immune-oncology company, Forty Seven, Inc., that works to develop therapies targeting cancer immune evasion pathways, has revealed clinical data from Phase 1b/2. The company is evaluating a new drug combination of Recombinant Human A...

FDA grants orphan drug tag to NuCana’s biliary tract cancer treatment
FDA grants orphan drug tag to NuCana’s biliary tract cancer treatment
By Mateen Dalal

NuCana is on its way to open a Global Phase III study of Acelarin in combination with cisplatin for patients who are suffering from the disease in 2019 NuCana plc recently announced that it has received Orphan Drug Designation for Acelarin, an inves...